RxDoctor Payments Data

Michelle Ryan

Family · Ballston Spa, NYNPI 1144316662

Payments from drug & device makers

$10,690in general payments, 2019–2025

Across 545 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$1K
  • Lilly USA, LLC$820
  • Pfizer$786
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$10,62999%
  • Education$20%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,690 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$39,352
Medicare patients
143
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide122$134,896
OzempicSemaglutide55$53,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$51,718
EliquisApixaban27$36,926
XareltoRivaroxaban29$36,486
TrulicityDulaglutide14$33,435
JardianceEmpagliflozin20$30,587
FarxigaDapagliflozin Propanediol18$17,269
GemtesaVibegron15$17,028
OxycontinOxycodone Hcl14$7,973
Rosuvastatin Calcium267$4,688
Levothyroxine Sodium227$4,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,654
Colchicine13$2,147
Atorvastatin Calcium184$2,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$820$168,330136 claims
Novo NordiskOzempic$1,987$53,71755 claims
GSKTrelegy Ellipta$1,075$51,71877 claims
PfizerEliquis$786$36,92627 claims
Johnson & JohnsonXarelto$63$36,48629 claims
Boehringer IngelheimJardiance$194$30,58720 claims
AstraZenecaFarxiga$1,395$17,26918 claims
Sumitomo Pharma America, Inc.Gemtesa$346$17,02815 claims
AbbVieSynthroid$1,240$2,03625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Ballston Spa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →